Key Points The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low. 10 stocks we like better than Bio-Rad Laboratories › Healthcare diagnostics product supplier Bio-Rad Laboratories (NYSE: BIO) notched twin beats in its just-released third quarter, but that wasn't enough for a choosy stock market. Investors sold out of the company's shares in the wake of that earnings report to leave it with ...

Key Takeaways Bio-Rad reported Q3 adjusted EPS of $2.26, missing estimates but rising 11.9% year over year.BIO's revenues grew 0.5% to $653 million, surpassing expectations on Life Science and Diagnostics sales.BIO's gross margin contracted 219 bps, while operating profit rose 1.2% and operating margin hit 10%.Bio-Rad Laboratories, Inc. (BIO) posted third-quarter 2025 adjusted earnings per share (EPS) of $2.26, which missed the Zacks Consensus Estimate by 1.74%. However, the bottom line increased 11.9% from ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.26 per share, missing the Zacks Consensus Estimate of $2.3 per share. This compares to earnings of $2.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1.74%. A quarter ago, it was expected that this maker of instruments used in biomedical research would post earnings of $1.93 per share when it actually produced earnings of $2.61, delivering a surprise of +35. ...

Bio-Rad Laboratories (NYSE:BIO) Q3 2025 Earnings Call October 29, 2025 05:00 PM ET Speaker2Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. At this time, I would like to welcome everyone to the Bio-Rad Laboratories Third Quarter 2025 Results Conference Call and Webcast. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. If you would like to ask a questi ...

Bio-Rad Laboratories, Inc. Third Quarter 2025 Financial Results October 29, 2025 2 Q3 2025 GAAP Financial Results Safe Harbor Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding management's goals, plans, and expectations, our future financial performance, our future financial projections, our growth strategy, and other matters. Forward looking statements general ...

收入和利润 - 2025年第三季度净销售额为6.53亿美元，同比增长0.5%，但按恒定汇率计算下降1.7%[131] - 2025年前九个月净销售额为18.9亿美元，同比下降0.5%，按恒定汇率计算下降0.7%[143] 成本和费用 - 2025年第三季度综合毛利率为52.6%，较2024年同期的54.8%下降2.2个百分点[134] - 2025年第三季度销售、一般及行政费用为2.068亿美元，占销售额的31.7%，主要由于员工相关和重组成本增加[135] - 2025年第三季度研发费用为7130万美元，占销售额的10.9%，同比下降主要与2024年收购相关的较高进程研发费用有关[136] - 2025年前九个月综合毛利率为52.6%，较2024年同期的54.6%下降2.0个百分点[146] - 2025年前九个月销售、一般及行政费用为6.233亿美元，占销售额的33.0%，主要由于重组成本增加[147] 投资公允价值变动 - 2025年第三季度权益证券和应收贷款公允价值变动导致亏损4.953亿美元，主要因对Sartorius AG的投资产生持有损失5.051亿美元[139] - 2025年前九个月权益证券和应收贷款公允价值变动导致亏损1.291亿美元，而2024年同期亏损为16.8亿美元[152] 现金流活动 - 截至2025年9月30日止九个月，经营活动产生的净现金为3.673亿美元，较2024年同期的3.31亿美元增长11%[160] - 截至2025年9月30日止九个月，用于投资活动的净现金为1.555亿美元，较2024年同期的1.297亿美元增长20%[161] - 截至2025年9月30日止九个月，用于融资活动的净现金为2.865亿美元，较2024年同期的1.926亿美元增长49%[162] 资本结构与融资活动 - 截至2025年9月30日，公司持有现金、现金等价物和短期投资共计14亿美元，其中约18%由海外子公司持有[156] - 公司拥有2亿美元的未担保循环信贷协议，有效期至2029年2月，截至2025年9月30日无未偿还借款，但570万美元用于国内备用信用证，减少了可用借款额度[157] - 公司于2022年3月发行高级票据获得12亿美元现金收益，其中4亿美元和8亿美元票据分别于2027年3月和2032年3月到期，年利率分别为3.3%和3.7%[158] 股票回购 - 公司在截至2025年9月30日止九个月内以2.955亿美元回购了1,205,381股A类普通股，而去年同期以2.036亿美元回购了690,857股[162] - 截至2025年9月30日，根据2023年股票回购计划，仍有2.846亿美元可用于回购[162]

Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2025 Financial Results HERCULES, Calif.—October 29, 2025 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2025. "During the third quarter, we continued to navigate a dynamic global environment and evolving conditions across the markets for our life science and clinical diagnostics products," stated ...

公司近期活动 - 公司首席执行官Seth Lederman医生将于2025年11月4日下午3点（中欧时间）在奥地利维也纳举行的BIO-Europe 2025会议上进行演讲[1] - 演讲内容将概述公司的战略和研发管线，并重点介绍近期的临床、监管和商业里程碑[2] - 会议期间可通过BIO One-on-One Partnering系统或联系指定代表预约与公司管理层会面[2] 公司业务与产品管线 - 公司是一家完全整合的生物技术公司，拥有已上市产品和处于研发阶段的候选产品[3] - 公司旗下Tonmya™已获得FDA批准，用于治疗影响数百万成年人的慢性疼痛疾病纤维肌痛，这是15年多以来首个获批的纤维肌痛新处方药[3] - 公司还销售两款用于成人急性偏头痛的治疗药物[3] - 公司研发管线专注于中枢神经系统疾病、免疫学、免疫肿瘤学、罕见病和传染病领域[3] 研发管线重点项目 - TNX-102 SL正在美国国防部资助的OASIS研究中，由北卡罗来纳大学根据医生发起的研究用新药申请进行开发，用于治疗急性应激反应和急性应激障碍，同时也在开发用于治疗重度抑郁症[3] - 免疫学产品组合包括TNX-1500，一种用于预防同种异体移植排斥和治疗自身免疫性疾病的Fc修饰人源化抗CD40配体单克隆抗体[3] - 罕见病产品组合包括TNX-2900，一种用于治疗普拉德-威利综合征的经镁强化的鼻内催产素[3] - 传染病产品组合包括TNX-801（一种正在开发用于预防猴痘和天花的疫苗）以及TNX-4800（一种用于季节性预防莱姆病的单克隆抗体）[3] - TNX-4200是一种针对CD45的小分子广谱抗病毒剂，公司与美国国防威胁降低局签订了一份为期五年、总额高达3400万美元的合同，用于在生物威胁环境中预防或治疗感染以改善军事人员的医疗准备状态[3] - 公司在马里兰州弗雷德里克拥有并运营一个先进的传染病研究机构[3]

Upslope Capital Management, an investment management company, released its third-quarter investor letter. A copy of the letter can be downloaded here. The third quarter was a strong one for the fund despite unusual volatility in the macro environment. The fund returned +8.8% (net) in Q3 compared to +5.5% and +3.8% for the S&P Midcap 400 ETF (MDY) and HFRX Equity Hedge Index, respectively. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025. In its third-quarter 2025 i ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Bio-Rad Laboratories (BIO) reports results for the quarter ended September 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on October 29, might help the stock move higher if these key numbers are better th ...